Publicacións nas que colabora con Eduardo Sobarzo Sánchez (20)

2019

  1. Aporphines and Alzheimer's Disease: Towards a Medical Approach Facing the Future

    Current medicinal chemistry, Vol. 26, Núm. 18, pp. 3253-3259

  2. In silico prediction of P-glycoprotein binding: Insights from molecular docking studies

    Current Medicinal Chemistry, Vol. 26, Núm. 10, pp. 1746-1760

  3. Potent in Vitro α-Glucosidase Inhibition of Secondary Metabolites Derived from Dryopteris cycadina

    Molecules, Vol. 24, Núm. 3

  4. Quercetin and related chromenone derivatives as monoamine oxidase inhibitors: Targeting neurological and mental disorders

    Molecules, Vol. 24, Núm. 3

2018

  1. Ligand and structure-based modeling of passive diffusion through the blood-brain barrier

    Current Medicinal Chemistry, Vol. 25, Núm. 9, pp. 1073-1089

  2. Nanomedicine and Parkinson’s disease: A nanoparticle medical approach

    Psychiatric and Mood Diseases and the Natural Compounds: An Approach to the Future Medical Tool (Nova Science Publishers, Inc.), pp. 153-168

2017

  1. A medical approach to the monoamine oxidase inhibition by using 7H-benzo[e]perimidin-7-one derivatives

    Current Topics in Medicinal Chemistry, Vol. 17, Núm. 7

  2. Aporphine alkaloids and their antioxidant medical application: From antineoplastic agents to motor dysfunction diseases

    Current Organic Chemistry, Vol. 21, Núm. 4, pp. 342-347

  3. Molecular docking and drug discovery in β-adrenergic receptors

    Current Medicinal Chemistry, Vol. 24, Núm. 39, pp. 4340-4359

2016

  1. Aporphines and parkinson’s disease: Medical tools for the future

    Current Topics in Medicinal Chemistry, Vol. 16, Núm. 17, pp. 1906-1909

2015

  1. Anxiolytic-like effects of 7H-benzo[e]perimidin-7-one derivatives through elevated plus-maze test in mice

    Current Topics in Medicinal Chemistry, Vol. 15, Núm. 17, pp. 1750-1754

  2. Nanoparticles in the treatment of mental disorders: A new tool in the psychiatric medication

    Current Topics in Medicinal Chemistry, Vol. 15, Núm. 4, pp. 282-286

2014

  1. Comparison of the antidepressive effects of trans-resveratrol and 5-methoxy-7H-dibenzo[de,h]quinolin-7-one.

    Current topics in medicinal chemistry, Vol. 14, Núm. 2, pp. 234-238

2013

  1. Host-guest interaction between new nitrooxoisoaporphine and β-cyclodextrins: Synthesis, electrochemical, electron spin resonance and molecular modeling studies

    Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, Vol. 102, pp. 226-234

  2. Synthetic oxoisoaporphine alkaloids: in vitro, in vivo and in silico assessment of antileishmanial activities.

    PloS one, Vol. 8, Núm. 10

2012

  1. Monoamino oxidase A: An interesting pharmacological target for the development of multi-target QSAR

    Mini-Reviews in Medicinal Chemistry, Vol. 12, Núm. 10, pp. 947-958

2011

  1. 2D MI-DRAGON: A new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins

    European Journal of Medicinal Chemistry, Vol. 46, Núm. 12, pp. 5838-5851

  2. NL MIND-BEST: A web server for ligands and proteins discovery-Theoretic-experimental study of proteins of Giardia lamblia and new compounds active against Plasmodium falciparum

    Journal of Theoretical Biology, Vol. 276, Núm. 1, pp. 229-249

2010

  1. New approaches to 6-oxoisoaporphine and tetrahydroisoquinoline derivatives

    Helvetica Chimica Acta, Vol. 93, Núm. 7, pp. 1385-1394

2004

  1. Tandem RCM of Dienynes for the Construction of Taxol-Type Carbocyclic Systems

    Organic Letters, Vol. 6, Núm. 2, pp. 193-196